News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  18th May 2012  
  Congratulations to Diana Hui Sin HAY for being awarded 2nd Prize in the 2012 Johnson & Johnson Asia Outstanding Graduate Thesis Award in Bio-tech.
 
 




Diana was awarded 2nd Prize in the 2012 Johnson & Johnson Asia Outstanding Graduate Thesis Award in Bio-tech, a highly competitive international award. She is one of two students from NUS who won the award.

“JJSI Asia Outstanding Graduate Thesis Award in Bio-tech” is an annual award sponsored by Johnson & Johnson Corporate Office of Science and Technology ( COSAT, www.jnjcosat.com/cosat ). The award aims to promote and recognize the best graduate students in Asia who have made significant contributions in the field of bio-tech related to life sciences.

Title of Thesis: DEAD-box helicase DP103, an novel essential regulator of NEMO SUMOylation and NFκB activation, defines the metastatic potential of human breast cancers

Abstract
Despite advances, 20% to 30% of patients with early breast cancers experience relapse with distant metastasis. Therefore, there is a pressing need to identify new markers and therapeutic targets for metastatic breast cancers. In this report we identify the DEAD-box helicase, DP103, as a novel prognostic marker that predicts and mediates metastasis of human breast cancers. Furthermore, we identify the molecular mechanism underlying this novel hitherto unidentified role of this helicase. We show that DP103's function in breast cancers is attributable to its ability to elevate the levels of matrix metalloproteinase MMP9 through the activation of the well characterized oncogenic transcription factor NFκB. We further delineate that activation of NFκB by DP103 depends on its ability to function as a positive cofactor for the SUMO conjugating enzyme PIASy, an enzyme necessary for SUMOylating NEMO, an essential component of NFκB signaling.


Figure Legend: Model of DP103 regulation in NFκB pathway under genotoxic stress
In normal or low invasive cancer cells, low expression of DP103 does not affect the normal reversible SUMOylation and deSUMOylation of NEMO upon genotoxic stress.  However, the presence of high DP103 in highly invasive tumors enhanced NEMO SUMOylation through increased recruitment of PIASy to the substrate NEMO, and at the same time by reducing the interaction of NEMO with the SUMO protease SENP2. These resulted in a constitutive activation of NFκB which accounts for the elevated levels of its associated metastatic genes like MMP9 and confers protection against apoptosis.


For more information on Vinay TERGAONKAR’s laboratory, please click here.